BR112022008639A2 - Tratamento de distúrbios do fígado - Google Patents
Tratamento de distúrbios do fígadoInfo
- Publication number
- BR112022008639A2 BR112022008639A2 BR112022008639A BR112022008639A BR112022008639A2 BR 112022008639 A2 BR112022008639 A2 BR 112022008639A2 BR 112022008639 A BR112022008639 A BR 112022008639A BR 112022008639 A BR112022008639 A BR 112022008639A BR 112022008639 A2 BR112022008639 A2 BR 112022008639A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- liver disorders
- disorders
- manifestations
- symptoms
- Prior art date
Links
- 210000004185 liver Anatomy 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
TRATAMENTO DE DISTÚRBIOS DO FÍGADO. A presente invenção refere-se a métodos e composições para tratar distúrbios no fígado, incluindo, sem limitação, esteato-hepatite não alcoólica, e sintomas e manifestações dos mesmos, em um paciente.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962933277P | 2019-11-08 | 2019-11-08 | |
US202063004403P | 2020-04-02 | 2020-04-02 | |
PCT/US2020/059522 WO2021092474A1 (en) | 2019-11-08 | 2020-11-06 | Treating liver disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022008639A2 true BR112022008639A2 (pt) | 2022-07-19 |
Family
ID=75849579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022008639A BR112022008639A2 (pt) | 2019-11-08 | 2020-11-06 | Tratamento de distúrbios do fígado |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4054567A4 (pt) |
JP (1) | JP2023501386A (pt) |
KR (1) | KR20220098168A (pt) |
CN (1) | CN114667142A (pt) |
AU (1) | AU2020380968A1 (pt) |
BR (1) | BR112022008639A2 (pt) |
CA (1) | CA3160445A1 (pt) |
CL (1) | CL2022001167A1 (pt) |
IL (1) | IL292459A (pt) |
MX (1) | MX2022005407A (pt) |
WO (1) | WO2021092474A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220184114A1 (en) | 2020-12-14 | 2022-06-16 | Regeneron Pharmaceuticals, Inc. | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
US20140187633A1 (en) * | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
CA3019496A1 (en) * | 2016-03-28 | 2017-10-05 | Intercept Pharmaceuticals, Inc. | Medicine obtained by combining fxr agonist and arb |
WO2018170173A1 (en) * | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
US20210121493A1 (en) * | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
KR20210052507A (ko) * | 2018-08-30 | 2021-05-10 | 테른스 파마슈티칼스, 인크. | 간 장애 치료 |
-
2020
- 2020-11-06 MX MX2022005407A patent/MX2022005407A/es unknown
- 2020-11-06 CN CN202080077929.8A patent/CN114667142A/zh active Pending
- 2020-11-06 JP JP2022526136A patent/JP2023501386A/ja active Pending
- 2020-11-06 WO PCT/US2020/059522 patent/WO2021092474A1/en unknown
- 2020-11-06 IL IL292459A patent/IL292459A/en unknown
- 2020-11-06 KR KR1020227018657A patent/KR20220098168A/ko unknown
- 2020-11-06 BR BR112022008639A patent/BR112022008639A2/pt not_active Application Discontinuation
- 2020-11-06 AU AU2020380968A patent/AU2020380968A1/en active Pending
- 2020-11-06 CA CA3160445A patent/CA3160445A1/en active Pending
- 2020-11-06 EP EP20886094.0A patent/EP4054567A4/en active Pending
-
2022
- 2022-05-04 CL CL2022001167A patent/CL2022001167A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2022005407A (es) | 2022-05-24 |
WO2021092474A1 (en) | 2021-05-14 |
EP4054567A4 (en) | 2024-01-10 |
JP2023501386A (ja) | 2023-01-18 |
CL2022001167A1 (es) | 2023-02-10 |
KR20220098168A (ko) | 2022-07-11 |
EP4054567A1 (en) | 2022-09-14 |
IL292459A (en) | 2022-06-01 |
CA3160445A1 (en) | 2021-05-14 |
AU2020380968A1 (en) | 2022-05-12 |
CN114667142A (zh) | 2022-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017026739A2 (pt) | compostos para uso no tratamento de distúrbios neuromusculares | |
BR112016026560A2 (pt) | Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção | |
BR112018005454A2 (pt) | administração de potencializadores de cftr deuterados | |
BR112015001847A2 (pt) | composições e tratamento para doenças e distúrbios nos olhos | |
BR112018076114A2 (pt) | composições tópicas de apremilast | |
PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
PH12017500829A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
BR112013031032A2 (pt) | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos | |
BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
BR112015005117A2 (pt) | métodos de tratamento da doença de alzheimer e suas composições farmacêuticas | |
EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
GB2503852A (en) | Compounds for the treatment of neuropsychiatric disorders | |
EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
MX2021002305A (es) | Tratamiento de trastornos del higado. | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
MX2017015012A (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
EA201690284A1 (ru) | Композиции и терапевтические способы для ускоренного регресса бляшки | |
BR112015000808A2 (pt) | regime de dosagem para inibidores de janus quinase (jak) | |
BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
BR112022023048A2 (pt) | Tratamento de combinação de distúrbios hepáticos | |
BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
BR112019004684A2 (pt) | combinação de agonistas de fxr | |
EA201200428A1 (ru) | Композиция и способ для лечения ожирения | |
BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |